US Treasury proposes curbs on Chinese biotech deals
China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
Newsletters and Deep Dive digital magazine
China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.
AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.
Editor's Picks
Newsletters and Deep Dive
digital magazine